Get the Stockscreener App
2.01
2.90%
-0.06
After Hours:
2.03
0.02
+1.00%
Taysha Gene Therapies Inc stock is traded at $2.01, with a volume of 3.09M.
It is down -2.90% in the last 24 hours and down -10.27% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
3.09M
Relative Volume:
1.60
Market Cap:
$410.91M
Revenue:
$12.87M
Net Income/Loss:
$-114.34M
P/E Ratio:
-0.8777
EPS:
-2.29
Net Cash Flow:
$-79.23M
1W Performance:
-0.99%
1M Performance:
-10.27%
6M Performance:
-29.97%
1Y Performance:
-36.39%
1-Day Range:
$1.98
$2.11
1-Week Range:
$1.98
$2.15
52-Week Range:
$1.27
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Taking a Closer Look At Taysha Gene Therapies Inc (TSHA) Following Its Recent Trade - Knox Daily
Market Highlights: Taysha Gene Therapies Inc (TSHA) Ends on a Low Note at 2.07 - The Dwinnex
Taysha Gene Therapies Inc (TSHA) can make a big difference with a little luck - SETE News
Taysha Gene Therapies' SWOT analysis: promising rett syndrome therapy drives stock potential - Investing.com
Taysha Gene Therapies Inc (TSHA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
TSHA Stock Sees Decline of Approximately -6.51% in Last Five Days - Knox Daily
Healthy Upside Potential: Taysha Gene Therapies Inc (TSHA) - SETE News
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress - The Manila Times
Taysha Gene Therapies Announces Oral Presentation on - GlobeNewswire
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress - StockTitan
Taysha Gene Therapies Inc’s results are impressive - US Post News
Closing Figures: Taysha Gene Therapies Inc (TSHA)’s Negative Finish at 2.03, Down -5.58 - The Dwinnex
Bank of New York Mellon Corp Takes Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
454,464 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Purchased by Bank of New York Mellon Corp - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average Target Price from Brokerages - Defense World
Taking a look at what insiders are doing to gauge the Taysha Gene Therapies Inc (TSHA)’s direction - Knox Daily
Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Canada Finance
TG Therapeutics Inc (TGTX) may enjoy gains as insiders got busy in the recent days - Knox Daily
IBD 50 Biotech Stock Rises On Five-Year Data For MS Drug - Investor's Business Daily
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
TG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High at $26.03 - MarketBeat
Tango Therapeutics Inc (TNGX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Closing Bell Recap: Taysha Gene Therapies Inc (TSHA) Ends at 2.17, Reflecting a -5.24 Downturn - The Dwinnex
Market Insights: TG Therapeutics Inc (TGTX)’s Notable Gain of 4.89, Closing at 24.89 - The Dwinnex
Ashton Thomas Private Wealth LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Tango Therapeutics Inc [TNGX] Investment Appeal on the Rise - Knox Daily
Tango Therapeutics (NASDAQ:TNGX) Shares Down 12.4% - MarketBeat
It makes sense and dollars to buy TG Therapeutics Inc (TGTX) stock - SETE News
TG Therapeutics stock soars to 52-week high of $25.71 - Investing.com India
A new trading data show Taysha Gene Therapies Inc (TSHA) is showing positive returns. - SETE News
Implant maker Tenon Medical nearly triples its market capitalization in two days - Kursiv Media
Tenon Medical stock jumps 73% in wake of Nasdaq listing update (NASDAQ:TNON) - Seeking Alpha
Tay-Sachs Disease Market to Witness Growth by 2032 | Companies - openPR
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Buying Buzz: Taysha Gene Therapies Inc [TSHA] 10% Owner Manning Paul B purchases 1,333,333 shares of the company – Knox Daily - Knox Daily
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Class Attys Vie To Lead Drug Co. Insider Trading Suit In Del. - Law360
Stock Surge: Taysha Gene Therapies Inc (TSHA) Closes at 2.07, Marking a 0.49 Increase/Decrease - The Dwinnex
Does Taysha Gene Therapies Inc (TSHA) offer a good opportunity for investors? - SETE News
Rett Syndrome Market Expected to Experience Major Growth - openPR
Checking in on Taysha Gene Therapies Inc (TSHA) after recent insiders movement - Knox Daily
Giant Axonal Neuropathy Market Growth to Accelerate in Forecast - openPR
Analytical Overview: Taysha Gene Therapies Inc (TSHA)’s Ratios Tell a Financial Story - The Dwinnex
A closer look at Taysha Gene Therapies Inc (TSHA)’s stock price trends - US Post News
Its Stock Has Paid Off Big Time For Taysha Gene Therapies Inc - SETE News
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average Price Target from Analysts - MarketBeat
TSHA (Taysha Gene Therapies) Enterprise Value : $344.05 Mil (As of Aug. 20, 2024) - GuruFocus.com
TSHA (Taysha Gene Therapies) Cash From Discontinued Investi - GuruFocus.com
Chardan Capital Equities Analysts Increase Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):